These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68 related articles for article (PubMed ID: 1556703)
1. Low dose cyclosporine A in psoriatic arthritis: relation between soluble interleukin 2 receptors and response to therapy. Salvarani C; Macchioni P; Boiardi L; Rossi F; Casadei Maldini M; Mancini R; Beltrandi E; Lodi L; Bisighini G; Portioli I J Rheumatol; 1992 Jan; 19(1):74-9. PubMed ID: 1556703 [TBL] [Abstract][Full Text] [Related]
2. Treatment of psoriatic arthritis with etanercept, methotrexate, and cyclosporin A. Gül U; Gönül M; Kiliç A; Erdem R; Cakmak SK; Gündüz H Clin Ther; 2006 Feb; 28(2):251-4. PubMed ID: 16678646 [TBL] [Abstract][Full Text] [Related]
3. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699 [TBL] [Abstract][Full Text] [Related]
4. Cyclosporine in the treatment of psoriatic arthritis. Gupta AK; Matteson EL; Ellis CN; Ho VC; Tellner DC; Voorhees JJ; McCune WJ Arch Dermatol; 1989 Apr; 125(4):507-10. PubMed ID: 2930208 [TBL] [Abstract][Full Text] [Related]
5. Sustained clinical response and high infliximab survival in psoriatic arthritis patients: a 3-year long-term study. Voulgari PV; Venetsanopoulou AI; Exarchou SA; Alamanos Y; Tsifetaki N; Drosos AA Semin Arthritis Rheum; 2008 Apr; 37(5):293-8. PubMed ID: 17888499 [TBL] [Abstract][Full Text] [Related]
6. Effects of cyclosporine A on serum and urinary soluble interleukin-2 receptor in patients with lupus nephritis. Tang Z; Zhang J; Zhang S; Li L Chin Med J (Engl); 1997 Sep; 110(9):686-9. PubMed ID: 9642325 [TBL] [Abstract][Full Text] [Related]
7. Interleukin-2 receptor levels in sera of patients with rheumatoid arthritis treated with sulfasalazine, parenteral gold, or placebo. Merkel PA; Dooley MA; Dawson DV; Pisetsky DS; Polisson RP J Rheumatol; 1996 Nov; 23(11):1856-61. PubMed ID: 8923356 [TBL] [Abstract][Full Text] [Related]
8. Cytokines and soluble interleukin 2 receptors in rheumatoid arthritis. Wolf RE; Brelsford WG; Hall VC; Adams SB J Rheumatol; 1992 Apr; 19(4):524-8. PubMed ID: 1593571 [TBL] [Abstract][Full Text] [Related]
9. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Fraser AD; van Kuijk AW; Westhovens R; Karim Z; Wakefield R; Gerards AH; Landewé R; Steinfeld SD; Emery P; Dijkmans BA; Veale DJ Ann Rheum Dis; 2005 Jun; 64(6):859-64. PubMed ID: 15528283 [TBL] [Abstract][Full Text] [Related]
10. Serial levels of soluble interleukin 2 receptor in the peripheral blood of patients with rheumatoid arthritis: correlations with disease activity. Rubin LA; Snow KM; Kurman CC; Nelson DL; Keystone EC J Rheumatol; 1990 May; 17(5):597-602. PubMed ID: 2359067 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. Furst DE; Saag K; Fleischmann MR; Sherrer Y; Block JA; Schnitzer T; Rutstein J; Baldassare A; Kaine J; Calabrese L; Dietz F; Sack M; Senter RG; Wiesenhutter C; Schiff M; Stein CM; Satoi Y; Matsumoto A; Caldwell J; Harris RE; Moreland LW; Hurd E; Yocum D; Stamler DA Arthritis Rheum; 2002 Aug; 46(8):2020-8. PubMed ID: 12209503 [TBL] [Abstract][Full Text] [Related]
13. Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study. Bongartz T; Coras B; Vogt T; Schölmerich J; Müller-Ladner U Rheumatology (Oxford); 2005 Jan; 44(1):126-9. PubMed ID: 15479756 [TBL] [Abstract][Full Text] [Related]
14. Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy. Dejica D Roum Arch Microbiol Immunol; 2001; 60(3):183-201. PubMed ID: 12165973 [TBL] [Abstract][Full Text] [Related]
16. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab. Cauza E; Spak M; Cauza K; Hanusch-Enserer U; Dunky A; Wagner E Rheumatol Int; 2002 Nov; 22(6):227-32. PubMed ID: 12426660 [TBL] [Abstract][Full Text] [Related]
17. Multidisciplinary focus on cyclosporin A. Salvarani C; Boiardi L; Macchioni P; Pipitone N; Catanoso M; Pigatto P J Rheumatol Suppl; 2009 Aug; 83():52-5. PubMed ID: 19661542 [TBL] [Abstract][Full Text] [Related]
18. Serum levels of IL-10, IL-6, IL-1ra, and sIL-2R in patients with psoriatic arthritis. Elkayam O; Yaron I; Shirazi I; Yaron M; Caspi D Rheumatol Int; 2000; 19(3):101-5. PubMed ID: 10776688 [TBL] [Abstract][Full Text] [Related]
19. Cyclosporine A in rheumatoid arthritis: randomized, placebo controlled dose finding study. Altman RD; Schiff M; Kopp EJ J Rheumatol; 1999 Oct; 26(10):2102-9. PubMed ID: 10529124 [TBL] [Abstract][Full Text] [Related]
20. Treatment with cyclosporin in patients with psoriatic arthritis: results of clinical assessment. Raffayová H; Rovenský J; Mális F Int J Clin Pharmacol Res; 2000; 20(1-2):1-11. PubMed ID: 11146896 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]